Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars Could Face 'Litigation Backlog' Without Patent Reforms, AAM Fears

Executive Summary

Category is still in its infancy, but the newly renamed generic association worries that products might never reach their full potential if launches are substantially delayed by IP disputes.

Advertisement

Related Content

GPhA Rebrands As AAM, Hopes To Change Tenor Of Drug Pricing Debate
PSCK9 Battle: Sanofi Not Negotiating Praluent Fate With Amgen; Ruling Possible By June
Make Interchangeability Great Again: Biosimilar Switching Studies Need US Comparators
Supreme Court Jumps Into Biosimilars Battle Over Launch Notification, Patent Dance
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120055

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel